{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T15:46:44Z","timestamp":1772725604362,"version":"3.50.1"},"reference-count":57,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004281","name":"National Science Centre, Poland","doi-asserted-by":"publisher","award":["2018\/31\/B\/NZ7\/02675"],"award-info":[{"award-number":["2018\/31\/B\/NZ7\/02675"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Metabolites"],"abstract":"<jats:p>Background: In this study, we aimed to compare metabolomic profiles, biodistribution, and detoxification patterns of the novel SN-38 derivative NMe with irinotecan (IR), and to identify NMe-specific metabolites to evaluate its preclinical pharmacokinetic advantages. Methods: In vivo ADME studies were conducted for NMe, a 9-aminomethyl SN-38 derivative, and IR following a single intraperitoneal dose of 40 mg\/kg in mice. Additionally, ADMET properties were predicted using ADMETlab and SwissADME tools for comparison. Levels of NMe and irinotecan absorbed into plasma, distributed to tissues, and metabolized were monitored in liver, lung, spleen, kidney, and stool samples at 15, 30, and 60 min post-administration. Tissue extracts were analysed using high-performance liquid chromatography (HPLC), liquid chromatography\u2013electrospray ionization quadrupole time-of-flight-tandem mass spectrometry (LC-ESI-QTOF-MS), and nuclear magnetic resonance (NMR) techniques after lyophilization and reconstitution. We compared the metabolomic profiles of irinotecan and NMe. Results: We identified and confirmed NMe-specific metabolites, including 9-CH2-S-cysteine conjugate, 9-CH2OH, and NMe-formyl. Notably, novel irinotecan metabolites (IR-OH and IR-\u0394E) were detected in small amounts in kidney samples. In some cases, two literature-known photodegradation products of irinotecan were present. NMe was found to quickly metabolize with different distribution to tissues, significantly greater to kidney and liver. Two SN-38 glucuronides, SN-38G(\u03b1) and SN-38G(\u03b2), were detected corresponding to \u03b1- and \u03b2-anomers. Where it was possible, NMe, IR and SN-38 were quantified using external calibration curves. In IR group, controlled and prolonged release of SN-38 was confirmed in all samples, yet SN-38G was observed in minority only in plasma, kidney, or lungs. In NMe groups, great relative amounts of SN-38 and SN-38G were detected. Greater content of SN-38G in NMe group than in irinotecan is expected to contribute to modulation and alleviation of some side effects in irinotecan-involved therapies, such as gastrointestinal toxicities (GIT). Conclusions: NMe shows a distinct metabolic profile characterized by rapid biotransformation, higher systemic glucuronidation of SN-38, and formation of unique metabolites, suggesting a potentially wider therapeutic window and reduced toxicity compared with IR.<\/jats:p>","DOI":"10.3390\/metabo16030172","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T14:19:21Z","timestamp":1772720361000},"page":"172","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Metabolomic Study of 7-Ethyl-9-(N-methyl)aminomethyl-10-hydroxycamptothecin Derivative (NMe)\u2014The Chemotherapeutic Drug Candidate Versus Irinotecan (IR) on a Mouse Model"],"prefix":"10.3390","volume":"16","author":[{"given":"Piotr","family":"Surynt","sequence":"first","affiliation":[{"name":"Department of Genetics, Maria Sk\u0142odowska-Curie National Research Institute of Oncology, Roentgena 5, 02-781 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3740-8387","authenticated-orcid":false,"given":"Beata","family":"Naumczuk","sequence":"additional","affiliation":[{"name":"Laboratory for Analysis of Bioactive Compounds, Institute of Organic Chemistry Polish Academy of Sciences, Kasprzaka 44\/52, 01-224 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Pop\u0142awska","sequence":"additional","affiliation":[{"name":"Falsified Medicines and Medical Devices Department, National Medicines Institute, Che\u0142mska 30\/34, 00-725 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7976-633X","authenticated-orcid":false,"given":"Magdalena","family":"Urbanowicz","sequence":"additional","affiliation":[{"name":"Falsified Medicines and Medical Devices Department, National Medicines Institute, Che\u0142mska 30\/34, 00-725 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3453-1590","authenticated-orcid":false,"given":"Katarzyna","family":"Unrug-Bielawska","sequence":"additional","affiliation":[{"name":"Department of Genetics, Maria Sk\u0142odowska-Curie National Research Institute of Oncology, Roentgena 5, 02-781 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Cybulska-Lubak","sequence":"additional","affiliation":[{"name":"Department of Genetics, Maria Sk\u0142odowska-Curie National Research Institute of Oncology, Roentgena 5, 02-781 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuzanna","family":"Sadowska-Markiewicz","sequence":"additional","affiliation":[{"name":"Department of Genetics, Maria Sk\u0142odowska-Curie National Research Institute of Oncology, Roentgena 5, 02-781 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9962-6024","authenticated-orcid":false,"given":"Jerzy","family":"Sitkowski","sequence":"additional","affiliation":[{"name":"Falsified Medicines and Medical Devices Department, National Medicines Institute, Che\u0142mska 30\/34, 00-725 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1275-8893","authenticated-orcid":false,"given":"El\u017cbieta","family":"Bednarek","sequence":"additional","affiliation":[{"name":"Falsified Medicines and Medical Devices Department, National Medicines Institute, Che\u0142mska 30\/34, 00-725 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Zeber-Lubecka","sequence":"additional","affiliation":[{"name":"Department of Genetics, Maria Sk\u0142odowska-Curie National Research Institute of Oncology, Roentgena 5, 02-781 Warsaw, Poland"},{"name":"Department of Gastroenterology, Hepatology and Clinical Oncology, Centre of Postgraduate Medical Education, Roentgena 5, 02-781 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lech","family":"Kozerski","sequence":"additional","affiliation":[{"name":"Falsified Medicines and Medical Devices Department, National Medicines Institute, Che\u0142mska 30\/34, 00-725 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3447-7328","authenticated-orcid":false,"given":"Micha\u0142","family":"Mikula","sequence":"additional","affiliation":[{"name":"Department of Genetics, Maria Sk\u0142odowska-Curie National Research Institute of Oncology, Roentgena 5, 02-781 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerzy","family":"Ostrowski","sequence":"additional","affiliation":[{"name":"Department of Genetics, Maria Sk\u0142odowska-Curie National Research Institute of Oncology, Roentgena 5, 02-781 Warsaw, Poland"},{"name":"Department of Gastroenterology, Hepatology and Clinical Oncology, Centre of Postgraduate Medical Education, Roentgena 5, 02-781 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJM200009283431302","article-title":"Miller Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer","volume":"343","author":"Saltz","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"606","DOI":"10.2165\/00003495-199652040-00013","article-title":"A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer","volume":"52","author":"Wiseman","year":"1996","journal-title":"Drugs"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00280-007-0588-3","article-title":"Tritherapy with fluorouracil\/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): A phase II study in colorectal cancer patients with non-resectable liver metastases","volume":"62","author":"Ychou","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.ctrv.2006.07.001","article-title":"Irinotecan in the treatment of colorectal cancer","volume":"32","author":"Fuchs","year":"2006","journal-title":"Cancer Treat. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1053\/sonc.2001.22534","article-title":"Beyond Pancreatic Cancer: Irinotecan and Gemcitabine in Solid Tumors and Hematologic Malignancies","volume":"28","author":"Lima","year":"2001","journal-title":"Semin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S508","DOI":"10.1016\/j.annonc.2024.08.708","article-title":"641P Phase I\/II clinical and pharmacokinetic study of ecubectedin in combination with irinotecan in patients with selected advanced solid tumors","volume":"35","author":"Vieito","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0169-5002(02)00081-8","article-title":"Phase I study of weekly CPT-11 (irinotecan)\/docetaxel in patients with advanced solid tumors","volume":"37","author":"Font","year":"2002","journal-title":"Lung Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/S0959-8049(02)80784-5","article-title":"Pilot studies of antimetabolites preceeded by irinotecan in advanced solid tumors","volume":"38","author":"Ramnath","year":"2002","journal-title":"Eur. J. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Bocian, W., Naumczuk, B., Urbanowicz, M., Sitkowski, J., Bednarek, E., Wiktorska, K., Pogorzelska, A., Wielgus, E., and Kozerski, L. (2022). Insight on the Interaction between the Camptothecin Derivative and DNA Oligomer Mimicking the Target of Topo I Inhibitors. Molecules, 27.","DOI":"10.3390\/molecules27206946"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/0006-2952(85)90499-X","article-title":"Action of camptothecin and its derivatives on deoxyribonucleic acid","volume":"34","author":"Fukada","year":"1985","journal-title":"Biochem. Pharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4629","DOI":"10.1021\/bi00437a018","article-title":"On the mechanism of topoisomerase I inhibition by camptothecin: Evidence for binding to an enzyme-DNA complex","volume":"28","author":"Hertzberg","year":"1989","journal-title":"Biochemistry"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"115710","DOI":"10.1016\/j.ejmech.2023.115710","article-title":"The recent developments of camptothecin and its derivatives as potential anti-tumor agents","volume":"260","author":"Wang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"ref_13","first-page":"2350","article-title":"Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: Did we miss something in CPT analogue molecular targets for treating human disease such as cancer?","volume":"7","author":"Li","year":"2017","journal-title":"Am. J. Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: The \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s40487-022-00215-2","article-title":"Liposomal Irinotecan Shows a Larger Therapeutic Index than Non-liposomal Irinotecan in Patient-Derived Xenograft Models of Pancreatic Cancer","volume":"11","author":"Barbier","year":"2023","journal-title":"Oncol. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s40265-017-0741-1","article-title":"Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma","volume":"77","author":"Lamb","year":"2017","journal-title":"Drugs"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1111\/cas.15377","article-title":"Liposomal irinotecan (Onivyde): Exemplifying the benefits of nanotherapeutic drugs","volume":"113","author":"Milano","year":"2022","journal-title":"Cancer Sci."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Falvo, E., Arcovito, A., Conti, G., Cipolla, G., Pitea, M., Morea, V., Damiani, V., Sala, G., Fracasso, G., and Ceci, P. (2020). Engineered Human Nanoferritin Bearing the Drug Genz-644282 for Cancer Therapy. Pharmaceutics, 12.","DOI":"10.20944\/preprints202010.0032.v1"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Ghanbari-Movahed, M., Kaceli, T., Mondal, A., Farzaei, M.H., and Bishayee, A. (2021). Recent Advances in Improved Anticancer Efficacies of Camptothecin Nano-Formulations: A Systematic Review. Biomedicines, 9.","DOI":"10.3390\/biomedicines9050480"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.2174\/1389450117666160502151707","article-title":"Strategies Targeting DNA Topoisomerase I in Cancer Chemotherapy: Camptothecins, Nanocarriers for Camptothecins, Organic Non-Camptothecin Compounds and Metal Complexes","volume":"17","author":"Gokduman","year":"2016","journal-title":"Curr. Drug Targets"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.addr.2007.11.009","article-title":"Polymer-drug conjugates: Recent development in clinical oncology","volume":"60","author":"Li","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"100787","DOI":"10.1016\/j.apmt.2020.100787","article-title":"Pathway-dependent supramolecular polymerization of camptothecin derivatives into filaments for chemotherapy and imaging","volume":"20","author":"Liang","year":"2020","journal-title":"Appl. Mater. Today"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"119701","DOI":"10.1016\/j.biomaterials.2019.119701","article-title":"Structure-based design of charge-conversional drug self-delivery systems for better targeted cancer therapy","volume":"232","author":"Xiao","year":"2020","journal-title":"Biomaterials"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"122886","DOI":"10.1016\/j.ijpharm.2023.122886","article-title":"Recent advances in SN-38 drug delivery system","volume":"637","author":"Yang","year":"2023","journal-title":"Int. J. Pharm."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1080\/00498250110057341","article-title":"Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin","volume":"31","author":"Hanioka","year":"2001","journal-title":"Xenobiotica"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1172\/JCI915","article-title":"Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes","volume":"101","author":"Iyer","year":"1998","journal-title":"J. Clin. Investig."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s40262-018-0644-7","article-title":"Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics","volume":"57","author":"Goey","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"ref_28","unstructured":"Kozerski, L., Kawecki, R., Naumczuk, B., Hyz, K., Bocian, W., Sitkowski, J., Bednarek, E., Wiktorska, K., and Lubelska, K. (2017). Derivatives of Camptothecin, a Method of Producing Them and Their Use. (US9682992B2)."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"128146","DOI":"10.1016\/j.bmcl.2021.128146","article-title":"New camptothecin derivatives for generalized oncological chemotherapy: Synthesis, stereochemistry and biology","volume":"46","author":"Naumczuk","year":"2021","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4219","DOI":"10.21873\/anticanres.17252","article-title":"Therapeutic Responses to Two New SN-38 Derivatives in Colorectal Cancer Patient-Derived Xenografts and Respective 3D In Vitro Cultures","volume":"44","author":"Earnshaw","year":"2024","journal-title":"Anticancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1021\/js970110c","article-title":"Photodegradation of Irinotecan (CPT-11) in Aqueous Solutions: Identification of Fluorescent Products and Influence of Solution Composition","volume":"86","author":"Dodds","year":"1997","journal-title":"J. Pharm. Sci."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Masella, R., and Mazza, G. (2009). Sulfur Amino Acids: An Overview. Glutathione and Sulfur Amino Acids in Human Health and Disease, John Wiley & Sons, Inc.","DOI":"10.1002\/9780470475973"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1021\/tx020079g","article-title":"Quenching of quercetin quinone\/quinone methides by different thiolate scavengers: Stability and reversibility of conjugate formation","volume":"16","author":"Awad","year":"2023","journal-title":"Chem. Res. Toxicol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3109\/10408448809037470","article-title":"Biosynthesis and biotransformation of glutathione S-conjugates to toxic metabolites","volume":"18","author":"Anders","year":"1988","journal-title":"Crit. Rev. Toxicol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.forsciint.2004.03.030","article-title":"Instability of pancuronium in postmortem blood and liver taken after a fatal intramuscular Pavulon injection","volume":"143","author":"Lechowicz","year":"2004","journal-title":"Forensic Sci. Int."},{"key":"ref_36","first-page":"75","article-title":"The Development and Validation of a Chiral High Performance Liquid Chromatography Method for the Identification and Quantification of (R)-Enantiomer in 10-Hydroxycamptothecin","volume":"25","author":"Venkateshwarlu","year":"2014","journal-title":"J. Braz. Chem. Soc."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1006\/bbrc.1999.0453","article-title":"Glucuronidation of 7-Ethyl-10-hydroxycamptothecin (SN-38) by the Human UDP-Glucuronosyltransferases Encoded at the UGT1 Locus","volume":"260","author":"Ciotti","year":"1999","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1124\/dmd.104.003491","article-title":"Differential Rates of Glucuronidation For 7-Ethyl-10-Hydroxy-Camptothecin (SN-38) Lactone and Carboxylate in Human and Rat Microsomes and Recombinant UDP-Glucuronosyl Transferase Isoforms","volume":"33","author":"Tallman","year":"2005","journal-title":"Drug Metab. Dispos."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1124\/mol.52.2.212","article-title":"Differential Expression of the UGT1A Locus in Human Liver, Biliary, and Gastric Tissue: Identification ofUGT1A7 and UGT1A10 Transcripts in Extrahepatic Tissue","volume":"52","author":"Strassburg","year":"1997","journal-title":"Mol. Pharmacol."},{"key":"ref_40","first-page":"3723","article-title":"Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea","volume":"54","author":"Gupta","year":"1994","journal-title":"Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1600-0773.1997.tb00289.x","article-title":"Glucuronidation of SN-38, the Active Metabolite of Irinotecan, by Human Hepatic Microsomes","volume":"80","author":"Haaz","year":"1997","journal-title":"Pharmacol. Toxicol."},{"key":"ref_42","first-page":"1505","article-title":"A New Metabolite of Irinotecan in Which Formation Is Mediated by Human Hepatic Cytochrome P-450 3a4","volume":"29","author":"Sai","year":"2001","journal-title":"Drug Metab. Dispos."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.fitote.2016.04.008","article-title":"Pharmacokinetic study of isocorynoxeine metabolites mediated by cytochrome P450 enzymes in rat and human liver microsomes","volume":"111","author":"Zhao","year":"2016","journal-title":"Fitoterapia"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1080\/004982597240532","article-title":"Major role of the CYP2C isozymes in deamination of amphetamine and benzphetamine: Evidence for the quinidine-specific inhibition of the reactions catalysed by rabbit enzyme","volume":"27","author":"Shiiyama","year":"1997","journal-title":"Xenobiotica"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Okyar, A., Piccolo, E., Ahowesso, C., Filipski, E., Hossard, V., Guettier, C., La Sorda, R., Tinari, N., Iacobelli, S., and L\u00e9vi, F. (2011). Strain- and Sex- Dependent Circadian Changes in Abcc2 Transporter Expression: Implicationsfor Irinotecan Chronotolerance in Mouse Ileum. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0020393"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"468","DOI":"10.3109\/07420528.2011.569043","article-title":"Sex and dosing-time dependencies in irinotecan-induced circadian disruption","volume":"28","author":"Ahowesso","year":"2011","journal-title":"Chronobiol. Int."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1124\/mol.109.056705","article-title":"Sex Differences in the Expression of Hepatic Drug Metabolizing Enzymes","volume":"76","author":"Waxman","year":"2009","journal-title":"Mol. Pharmacol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.2217\/pgs.10.95","article-title":"Irinotecan pharmacogenomics","volume":"11","author":"Marsh","year":"2010","journal-title":"Pharmacogenomics"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.chembiol.2015.08.005","article-title":"Structure and Inhibition of Microbiome \u03b2-Glucuronidases Essential to the Alleviation of Cancer Drug Toxicity","volume":"22","author":"Wallace","year":"2015","journal-title":"Chem. Biol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10928-010-9181-1","article-title":"Physiologically based pharmacokinetic model for topotecan in mice","volume":"38","author":"Shah","year":"2011","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Tillement, J.-P., and Tremblay, D. (2007). Clinical Pharmacokinetic Criteria for Drug Research. Comprehensive Medicinal Chemistry II, Elsevier.","DOI":"10.1016\/B0-08-045044-X\/00117-6"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s002800050801","article-title":"Comparison of the pharmacokinetics and efficacy of irinotecan after administration by the intravenous versus intraperitoneal route in mice","volume":"42","author":"Guichard","year":"1998","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_54","unstructured":"(2024, October 01). Available online: https:\/\/chemicalize.com\/."},{"key":"ref_55","unstructured":"(2024, October 01). Available online: https:\/\/vcclab.org\/lab\/alogps\/."},{"key":"ref_56","unstructured":"(2024, October 01). Available online: https:\/\/admetmesh.scbdd.com\/."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Dulsat, J., L\u00f3pez-Nieto, B., Estrada-Tejedor, R., and Borrell, J.I. (2023). Evaluation of Free Online ADMET Tools for Academic or Small Biotech Environments. Molecules, 28.","DOI":"10.3390\/molecules28020776"}],"container-title":["Metabolites"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-1989\/16\/3\/172\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T14:49:00Z","timestamp":1772722140000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-1989\/16\/3\/172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,5]]},"references-count":57,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["metabo16030172"],"URL":"https:\/\/doi.org\/10.3390\/metabo16030172","relation":{},"ISSN":["2218-1989"],"issn-type":[{"value":"2218-1989","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,5]]}}}